|
Patent landscape, scope, and claims summary: |
Analyzing the Claims and Patent Landscape of United States Patent 4,450,103
Introduction
United States Patent 4,450,103, titled "Process for the Production of Interferon," is a significant patent in the field of biotechnology, particularly in the production of interferon-β (IFN-β). This analysis will delve into the claims of the patent, the technological context, and the broader patent landscape to provide a comprehensive understanding.
Patent Overview
Patent Details
- Patent Number: 4,450,103
- Filing Date: Not specified in the provided sources, but typically filed in the early 1980s given the patent's issuance date.
- Issuance Date: Likely in the mid-1980s, as it is referenced in later patents such as US5814485A[5].
Inventors and Assignees
The patent is likely assigned to a biotechnology company, such as Cetus Corporation, which was a prominent player in the field during that era. Inventors would typically include scientists and researchers involved in the development of the interferon production process.
Claims Analysis
Key Claims
The patent primarily focuses on a process for producing interferon-β (IFN-β) using recombinant DNA technology. Here are some key aspects of the claims:
- Cell Disruption and Extraction: The process involves disrupting the cell membranes of bacteria that have been transformed with the IFN-β gene to release the interferon. This is followed by solubilization and purification steps to isolate the IFN-β[5].
- Recombinant DNA Techniques: The patent describes the use of recombinant DNA sequences to encode IFN-β, which are then expressed in bacterial hosts. This involves the construction of expression vectors and the transformation of host cells[5].
Technological Significance
The claims highlight a crucial advancement in biotechnology:
- Efficient Production: The process enables the large-scale production of IFN-β, which was a significant challenge at the time. This was critical for therapeutic applications, as IFN-β is used to treat various diseases, including multiple sclerosis.
- Purity and Yield: The method ensures a higher purity and yield of IFN-β, making it more viable for clinical use.
Patent Landscape Analysis
Geographical Spread
- The geographical spread of patents related to interferon production is predominantly in countries with advanced biotechnology sectors, such as the United States, Europe, and Japan. Companies and research institutions in these regions have been at the forefront of biotechnological innovations[3].
Saturation of Patent Space
- The patent space for interferon production was relatively saturated by the late 1980s, with multiple patents filed by various companies. This saturation indicates a highly competitive and innovative field where companies were continually improving production methods and formulations[3].
Key Players
- Cetus Corporation: As one of the early leaders in biotechnology, Cetus Corporation held several patents related to interferon production, including those involving recombinant DNA techniques and mutein technology[1][5].
- Other Competitors: Other companies and research institutions, such as Biogen and Genentech, were also active in this space, contributing to the development of interferon-based therapies.
Time-Slicing and Trends
- Early Innovations: The early 1980s saw a surge in patents related to interferon production, reflecting the initial wave of innovation in this field.
- Continuous Improvement: Over time, there has been a continuous stream of patents focusing on improving the production process, enhancing purity, and developing new formulations. This trend indicates ongoing research and development in the field[3].
Strategic Insights
Patentability and Landscape Analysis
- A thorough patent landscape analysis would reveal that while the specific claims of US 4,450,103 are focused on a particular process, the broader landscape includes a wide range of related technologies. This includes mutein technology, where cysteine residues are modified to improve protein stability, and other recombinant DNA techniques[1][4].
- Niche Areas: Identifying underappreciated niche areas, such as specific mutations or expression systems, can provide strategic insights for companies looking to innovate within this space without infringing existing patents[3].
Secondary Considerations and Obviousness
Non-Obviousness
- The patent's non-obviousness would be evaluated based on the state of the art at the time of filing. Given the innovative nature of recombinant DNA technology in the early 1980s, the process described in US 4,450,103 would likely have been considered non-obvious to a person of ordinary skill in the art.
- Recent Developments: The recent shift in the approach to evaluating obviousness, as seen in the Federal Circuit's decision to adopt a more flexible approach, could impact how similar patents are evaluated in the future. This new framework emphasizes a more common-sense approach to obviousness, considering the level of ordinary skill in the art and the scope and content of prior art[2].
Key Takeaways
- Innovative Process: US 4,450,103 describes an innovative process for producing IFN-β using recombinant DNA technology.
- Competitive Landscape: The patent landscape for interferon production is highly competitive and saturated, with multiple players contributing to advancements.
- Strategic Insights: A comprehensive patent landscape analysis can provide valuable insights for companies looking to innovate and navigate this complex patent space.
- Evolving Legal Framework: The legal framework for evaluating obviousness is evolving, which could impact future patent applications and challenges.
FAQs
-
What is the main focus of US 4,450,103?
- The main focus is on a process for producing interferon-β (IFN-β) using recombinant DNA technology.
-
Who were the key players in the interferon production patent space during the 1980s?
- Key players included Cetus Corporation, Biogen, and Genentech.
-
How has the patent landscape for interferon production evolved over time?
- The landscape has evolved with continuous improvements in production processes, purity, and formulations, reflecting ongoing research and development.
-
What is the significance of mutein technology in the context of interferon production?
- Mutein technology involves modifying cysteine residues to eliminate intermolecular crosslinking and incorrect disulfide bridge formation, enhancing protein stability and biological activity.
-
How does the recent change in the obviousness test for design patents impact utility patents like US 4,450,103?
- While the change specifically affects design patents, the adoption of a more flexible approach to obviousness could influence how utility patents are evaluated in terms of considering a broader range of prior art and secondary considerations.
More… ↓
⤷ Subscribe
|
